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The superfamily of two pore-domain K+ (K2P) channels has a least 15
members,1 of which mainly TASK1 is expressed in cardiac myocytes.
TASK1 gating is voltage independent, but the channel is acid sensitive,
being activated by alkalotic conditions. Ion currents carried by TASK1
likely contribute to the cardiac action potential duration (APD), and
pharmacological inhibition of TASK1 lengthens the APD2,3 while
TASK1 knock-out animals display a long QT on the electrocardio-
gram.4,5 Interest in TASK1 channels has been mounting, because
their activity in various cell types seems critical for several physiologic-
al processes while their changed expression and/or function may
underlie many disease conditions. The channels are potential targets
for diverse therapeutic actions, including antiarrhythmic, antihyperten-
sive, antiepileptic, and antidepressive treatments as well as analgesia
and inhalation anaesthesia.6 Therefore, identifying the signalling path-
ways involved in their regulation is important. Newly available inves-
tigation tools, such as those used in the study of Schiekel et al.7
published in the current issue of Cardiovascular Research, allow one
to investigate the signalling pathways for the regulation of TASK1 in
intact cells while monitoring cell membrane lipid metabolism.
A well-recognized regulation of TASK1 channels is their inhibition by
receptors coupled to the G-protein Gp, which is linked to membrane
phospholipid breakdown via the activation of phospholipase C (PLC).
Neurotransmitters such as norepinephrine (acting on a–adrenergic
receptors), hormones such angiotensin or endothelin-1, and other ago-
nists (e.g. platelet-activating factor, PAF) reduce TASK1 ion currents.1
The signalling pathway linking Gp activation to TASK1 inhibition has
been a source of controversy, given variable and inconsistent results
obtained in different cell systems. Some studies have suggested a role
of TASK1 phosphorylation by protein kinase C (PKC) while others
did not find any evidence for involvement of the kinase. Similarly,
some studies have provided evidence for involvement of phosphatidyl-
inositol bisphosphate (PIP2) breakdown while others obtained evidence
for the opposite. Nearly all possible steps, including a direct TASK1
inhibition by Gp subunits, have found supporting and opposing evi-
dence. Such variability in the results may simply reflect the diversity
of PLC and PKC isozymes and of other possible transducers and effec-
tors involved in the various cells.
Identifying the signalling pathways for cardiac endothelin-1 effects is
important given the increased circulating and intramyocardial levels of
the peptide in conditions such as hypertrophy, heart failure, and acute
ischaemia. Using rat ventricular myocytes, Schiekel et al.7 demonstrate
that endothelin-1-mediated inhibition of sustained K+ currents in
cardiac cells occurs via subtype-A receptors and involves an effect
on TASK1. The study further explores the signalling pathways and
provides results that challenge paradigms (e.g. the involvement of
PKC) that are accepted for other cells types or for other cardiac Gq-
coupled receptors. PLC is implicated given the suppression of the
endothelin-1 effect following a pretreatment with the PLC inhibitor
U73122. The effects can be reconstituted in a heterologous expres-
sion system, where endothelin-1-induced breakdown of PIP2 as a
result of PLC activation can be readily demonstrated. This study
shows that the mechanisms involved in the inhibition of cardiac
TASK1 lie downstream of the Gp subunits, implicated as acting direct-
ly on TASK1 in other systems. Having established an involvement of
PLC, three possible signalling pathways downstream of the enzyme
can be invoked: (i) the accumulation of IP3, (ii) the accumulation of
diacylglycerol (DAG), or (iii) the depletion of PIP2. While IP3 usually
acts by releasing Ca2+ from intracellular stores, and DAG by activat-
ing PKC, they may also act directly on channels. Indirect IP3-mediated
regulation of TASK1 via Ca2+ release is unlikely because the regula-
tion of the channels is insensitive to a blockade of Ca2+ release
from the sarcoplasmic reticulum.8 In addition, although IP3-induced
Ca2+ release can occur in cardiac cells, it is usually of minor signifi-
cance compared with Ca2+-induced Ca2+ release. Also, direct IP3 in-
jection in oocytes failed to inhibit TASK1.8 Concerning DAG, indirect
action via PKC1 is involved in the PAF-induced inhibition of TASK1
and its resultant arrhythmogenic effect in mouse ventricular cells
since these effects could be reproduced by PKC activators and pre-
vented by PKC inhibitors.9 However, the PKC1 phosphorylation site
is located in a non-conserved region of TASK1, leaving the possibility
that TASK1 in cardiomyocytes of other species may respond differ-
ently. In the study of Schiekel et al.7 an involvement of PKC is
The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology.
* Corresponding author: Campus Gasthuisberg, Herestraat 49, Box 705, B-3000, Leuven, Belgium. Tel: +32 16 330808; fax: +32 16 330809. Email: kanigula.mubagwa@med.kuleuven.be
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com.
Cardiovascular Research (2013) 97, 10–12
doi:10.1093/cvr/cvs343
by guest on Novem
ber 13, 2014
D
ow
nloaded from
 
excluded in the endothelin-1 effects, which were insensitive to PKC
inhibitors.
Having ruled out roles for IP3 and PKC in the endothelin-1 effect on
cardiac TASK1, one is apparently left with the depletion of PIP2 as the
remaining hypothesis. This hypothesis is very attractive given the
reported role of PIP2 as a major channel regulator. Requirement of
PIP2 for channel gating has been proposed when manipulations that
likely deplete PIP2 cause channel closure or rundown, whereas man-
oeuvers that replenish PIP2 restore or allow sustained channel activity.
In cardiac cells, requirement of PIP2 has been proposed for various K
+
channels, including KV7-KCNE1 (IKs), Kir2.1 (IK1), IK2ACh, and IKATP
channels as well as for other channels. However, it is being increasing-
ly recognized that the ability of exogenous PIP2 to restore channel ac-
tivity may not be a sufficient proof for a PIP2 regulation of these
channels under physiological conditions. Indeed, many channels
reported to be PIP2 sensitive in experiments on isolated membrane
patches do not respond to protocols of PIP2 depletion in intact
cells, suggesting that non-physiologically high PIP2 concentrations
used experimentally may form micelles and/or may interact with
channel domains that are not affected by physiological levels of the
phospholipid.10 PLC activation by physiological factors may not be suf-
ficient to reduce PIP2 to levels below those needed for channel acti-
vation, especially under conditions where synthesis of PIP2 by lipid
kinases remain active and/or when the channel displays high affinity
for PIP2. Using novel protocols of PIP2 depletion from the cell mem-
brane, it was recently shown that the TASK1 activity in CHO cells
is unaffected by the lipid depletion,11 making unsustainable the
apparently remaining hypothesis of PIP2 depletion as a mediator of
the effect of endothelin-1.
Obviously, other mechanisms have to be invoked for the
endothelin-1 inhibition on cardiac TASK1, including (i) a direct
action of PLC itself, (ii) a PKC-independent effect of DAG or, as sug-
gested by Schiekel et al.,7 (iii) an effect of DAG metabolites. Direct
channel regulation by PLC is known to exist for TRPC3 through for-
mation of an intermolecular lipid-binding domain.12 Concerning a
direct action of DAG itself, there are many examples of channel
modulation by this lipid, including an inhibition of TREK, another
K2P channel.
13 A possible direct effect of DAG on cardiac TASK1
has not been tested, but in carotid body cells, where the channel
may be involved in detecting hypoxia, oleoyl–acetylglycerol, a DAG
analogue, had no effect in the presence of PKC inhibitors, making it
unlikely that the lipid can directly inhibit TASK1.14 Similarly, DAG
failed to inhibit neuronal TASK channels.13 The only remaining possi-
bility is that of an involvement of DAG metabolites. It is of interest to
note that arachidonoyl-ethanolamide, also called anandamide, which
can be derived from membrane phospholipids (Figure 1) by the
action of a PLC,15,16 is an inhibitor of TASK1. Anandamide is an en-
dogenous cannabinoid but its effects on TASK1 are independent of
cannabinoid receptors. 2–Arachidonoyl-glycerol, another endogen-
ous cannabinoid structurally very close to anandamide, can be pro-
duced from DAG by a DAG lipase (Figure 1), but its effects on
TASK1 are unknown. Other possible metabolites include arachidonic
acid and phosphatidic acid. Some members of the K2P channel family
are sensitive to arachidonic acid, which however stimulates rather that
inhibits them as would be expected if the lipid were to mediate the
effect of endothelin-1. Phosphatidic acid failed to inhibit neuronal
TASK.13 Obviously, additional experiments using modulators of the
enzymes involved in the formation/breakdown of DAG metabolites
are needed in order to elucidate the signalling between Gp-coupled
receptors and TASK1, but it is likely that the pathways are diverse,
reflecting the diversity of enzymes and channels involved in each
cell. Modulating the pathways implicated in the regulation of cardiac
TASK1 could be of clinical relevance to prevent arrhythmogenic
actions of endothelin-1 in conditions such as hypertrophy, heart
failure, and acute myocardial ischaemia.17 In addition, activating
TASK1 or opposing its inhibition by endothelin-1 may also contribute
to reducing Ca2+ influx during the action potential, hence reducing
the rise in intracellular Ca2+, which likely plays a role in the remodel-
ling process associated with hypertrophy.
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